CTP-543 Patent Hearing Transcripts

Concert Pharmaceuticals is in patent battle with Incyte Corporation over CTP-543, which is deuterated Ruxolitinib. Ruxolitinib is owned by Incyte Corporation and is FDA approved for certain cancer indications such as myelofibrosis. The transcripts of the patent hearing that took place in January is here hearing - transcript.  The verdict will be announced in April. After reading the transcripts, I believe the counsel for Concert did well enough in the patent dispute to win, which will allow the company to advance CTP-543 forward for auto-immune indications such as Alopecia Areata. If by chance the ruling falls against Concert Pharmaceuticals, then the company has already stated that it will advance the patent dispute to circuit court. Thank you for reading.

Vertex Cystic Fibrosis Program

Vertex Pharmaceuticals (VRTX) has been, and will continue to be the leader in therapy for people with Cystic Fibrosis. Below is an update of all the different drugs in clinical trials that the company is currently running, including deuterated ivacaftor (VX-561), formerly known as CTP-656 that was purchased for $160 million from Concert Pharmaceuticals in July. Concert is eligible for up to $90 million more, dependent upon how far VX-561 progresses.

Twice Daily  
Ivacaftor 
Ivacaftor + Lumacaftor
Ivacaftor + Tezacaftor

Twice Daily Triple Combo Phase 2
Ivacaftor + Tezacaftor + VX-440 
Ivacaftor + Tezacaftor + VX-152
Ivacaftor + Tezacaftor + VX-659
Ivacaftor + Tezacaftor + VX-445

Once Daily Triple Combo Phase 2
VX-561 + Tezacaftor + VX-659 readout March 2018
VX-561 + Tezacaftor + VX-445 readout April 2018

The Ivacaftor patent runs to 2027, the Deuterated Ivacaftor (VX-561) patent runs into 2031. The goal for the program is to create a triple combo (1 potentiator, 2 correctors) once daily dosing for the majority of CF people with the F508del mutation. The company plans to run phase 3 triple combo trials in 2018.  Thank you for reading.